Verrucous Keratoses Associated with Checkpoint Inhibitor Immunotherapy

Joshua L. Owen, Cory Kosche, Jennifer N. Choi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Introduction: Checkpoint inhibitor immunotherapy is associated with numerous adverse events, including eruptive keratoacanthomas and squamous cell carcinomas. However, no cases of immunotherapy-associated verrucous keratoses (VKs) have been reported. VKs are proliferative lesions generally considered benign, although they have been suggested to represent premalignant lesions. Cases: We present the first case series of three patients with immunotherapy-associated VKs. The patients were receiving nivolumab for renal cell carcinoma, combination ipilimumab/nivolumab for non-small cell lung carcinoma, and pembrolizumab for malignant melanoma. The VKs appeared 3-7 months after initiation of immunotherapy. Lesions were treated with shave removal or cryosurgery without recurrence. This report adds to the spectrum of cutaneous squamoproliferative lesions induced by checkpoint inhibitor immunotherapy.

Original languageEnglish (US)
Pages (from-to)64-67
Number of pages4
JournalSKIN: Journal of Cutaneous Medicine
Issue number1
StatePublished - Jan 28 2020


  • PD-1
  • PD1
  • VK
  • checkpoint inhibitor
  • immunotherapy
  • irAE
  • nivolumab
  • squamoproliferative
  • verrucous keratosis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Verrucous Keratoses Associated with Checkpoint Inhibitor Immunotherapy'. Together they form a unique fingerprint.

Cite this